SDZ 220-581
Modify Date: 2025-08-20 19:06:36
SDZ 220-581 structure
|
Common Name | SDZ 220-581 | ||
|---|---|---|---|---|
| CAS Number | 174575-17-8 | Molecular Weight | 369.737 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 613.3±65.0 °C at 760 mmHg | |
| Molecular Formula | C16H17ClNO5P | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 324.7±34.3 °C | |
Use of SDZ 220-581SDZ 220-581 is a potent, competitive antagonist at the NMDA glutamate receptor subtype(pKi= 7.7).IC50 Value: Target: NMDA receptorin vitro: Wake-promoting doses of LSN2463359 and LSN2814617 attenuated deficits in performance induced by the competitiveNMDA receptor antagonist SDZ 220,581 in two tests of operant behaviour: the variable interval 30 s task and the DMTP task [1].in vivo: Administration of SDZ 220-581 or CGS 19755 was associated with a robust reduction in PPI, whereas L-701,324, 4-Cl-KYN or MLA failed to alter PPI [2]. With the most active agent, SDZ 220-581, full protection against maximal electroshock seizures (MES) was obtained at oral doses of 10 mg/kg in rats and in mice. The compound had a fast onset (< or = 1 hr) and a long duration (> or = 24 hr) of action [3]. Rats were pretreated with clozapine (0 or 5.0 mg/kg) or haloperidol (0 or 0.1 mg/kg), together with SDZ 220-581 (0 or 2.5 mg/kg), and tested. SDZ 220-581 and SDZ EAB-515 decreased PPI without affecting startle magnitude [4]. |
| Name | SDZ 220-581,(S)-α-Amino-2'-chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoicacid |
|---|---|
| Synonym | More Synonyms |
| Description | SDZ 220-581 is a potent, competitive antagonist at the NMDA glutamate receptor subtype(pKi= 7.7).IC50 Value: Target: NMDA receptorin vitro: Wake-promoting doses of LSN2463359 and LSN2814617 attenuated deficits in performance induced by the competitiveNMDA receptor antagonist SDZ 220,581 in two tests of operant behaviour: the variable interval 30 s task and the DMTP task [1].in vivo: Administration of SDZ 220-581 or CGS 19755 was associated with a robust reduction in PPI, whereas L-701,324, 4-Cl-KYN or MLA failed to alter PPI [2]. With the most active agent, SDZ 220-581, full protection against maximal electroshock seizures (MES) was obtained at oral doses of 10 mg/kg in rats and in mice. The compound had a fast onset (< or = 1 hr) and a long duration (> or = 24 hr) of action [3]. Rats were pretreated with clozapine (0 or 5.0 mg/kg) or haloperidol (0 or 0.1 mg/kg), together with SDZ 220-581 (0 or 2.5 mg/kg), and tested. SDZ 220-581 and SDZ EAB-515 decreased PPI without affecting startle magnitude [4]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 613.3±65.0 °C at 760 mmHg |
| Molecular Formula | C16H17ClNO5P |
| Molecular Weight | 369.737 |
| Flash Point | 324.7±34.3 °C |
| Exact Mass | 369.053284 |
| PSA | 130.66000 |
| LogP | 0.89 |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.637 |
| Storage condition | 2-8℃ |
| (2S)-2-Amino-3-[2'-chloro-5-(phosphonomethyl)-3-biphenylyl]propanoic acid |
| sdz 220-581 |